CD38 and acute lymphoblastic leukemia: Currently, two clinical trials of Daratumumab for the treatment of patients with r/r T‐ALL are being conducted.[26] The safety and promising efficacy of anti‐CD38 mAb‐based treatments have prompted the idea to use CD38‐specific CAR‐T or CAR‐NK therapies to treat T‐ALL.